Logo
  • About
  • Technology
  • News
  • Contact
Logo
  • About
  • Technology
  • News
  • Contact
20
Feb
2019

Come meet us at DK Bio 2019

We will be joining an exciting ensemble of Danish biotech companies travelling to New York to present Insusense’s technology!

News

7-11 January 2019: Meet Insusense Therapeutics in San Francisco at this year’s JP Morgan biotech conference
7. January 2019
Insusense Therapeutics website launches
4. January 2019
Paul Little, Operating Partner in Lundbeckfonden Emerge, replaces Christian Elling as CEO of Insusense Therapeutics
1. October 2018
Lundbeck Foundation doubles its investment in Aarhus-based Insusense Therapeutics
20. October 2015

About Us

InsuSence Therapeutics is a product-focused biotechnology company based on novel breakthrough science in diabetes biology, which has the potential to quantum leap to important new Type 2 diabetes therapeutics.

News

7-11 January 2019: Meet Insusense Therapeutics in San Francisco at this year’s JP Morgan biotech conference
7. January 2019
Insusense Therapeutics website launches
4. January 2019
Paul Little, Operating Partner in Lundbeckfonden Emerge, replaces Christian Elling as CEO of Insusense Therapeutics
1. October 2018

Contact

Insusense ApS
c/o Lundbeckfonden
Scherfigsvej 7
DK-2100 Copenhagen

  • Privacy Policy
Copyright © InsuSense Therapeutics, All Rights Reserved.